The psychostimulant amphetamine (AMPH) has an impact on a variety of cellular activities in striatal neurons, although underlying signaling mechanisms are incompletely understood. The Src family kinase (SFK) is among key signaling molecules enriched in striatal neurons and is involved in the regulation of a set of discrete downstream targets. Given the likelihood that AMPH may regulate SFKs, we investigated and characterized the effect of AMPH on SFK phosphorylation and enzymatic activity in rat striatal neurons in vivo. We found that AMPH elevated SFK Y416 phosphorylation in striatal slices and the adult rat striatum. This elevation was concentration-and time-dependent and occurred in all subdivisions of the striatum, including the caudate putamen and nucleus accumbens (core and shell). The dopamine D 1 receptor antagonist SCH23390 blocked the effect of AMPH. Between Fyn and Src, AMPH elevated phosphorylation of immunoprecipitated Fyn but not Src and increased Fyn kinase activity in the striatum. In parallel with SFKs, striatal ERK phosphorylation was increased by AMPH. This increase in ERK phosphorylation was reduced by the SFK inhibitor PP2. These results demonstrate that AMPH is able to activate SFKs (mainly Fyn) in striatal neurons via a D 1 receptor-dependent mechanism. Activated SFKs participate in processing the concomitant ERK response to AMPH.
Introduction
Phosphorylation is an important posttranslational modification of proteins in expression, trafficking, and function. One of amino acids that is subjected to phosphorylation is tyrosine, at which phosphorylation was catalyzed by either receptor or non-receptor tyrosine kinases. The latter include several subfamilies of kinases (Neet and Hunter, 1996) . Among them, the Src family kinase (SFK) has drawn the most attention. Src and Fyn are key SFK members and are enriched in the brain (Ohnishi et al., 2011) . Consistent data show that Src and Fyn directly bind to a large number of substrates in brain cells. By phosphorylating specific tyrosine site(s), Src and Fyn modify their distribution and function and are linked to the pathogenesis of various neuropsychiatric and neurological disorders (Kalia et al., 2004; Ohnishi et al., 2011; Schenone et al., 2011) . Of note, Src and Fyn themselves are regulated by a phosphorylation-dependent mechanism. In response to changing synaptic input, Src and Fyn can be phosphorylated at a conserved residue, tyrosine 416 (Y416), in the activation loop by an autophosphorylation mechanism, which leads to activation of these enzymes (Roskoski, 2005; Okada, 2012) .
Dopamine is an essential transmitter in the brain. A major dopamine responsive region is the striatum, a key structure in the mesolimbic reward system important for mood, cognition, and movement and linked to addictive properties of drugs of abuse. In the striatum, medium spiny projection neurons make up about 95% of the total population of striatal neurons. These neurons are classified equally into two subpopulations: striatonigral and striatopallidal neurons, giving rise to the direct and indirect pathway in the basal ganglia, respectively. Noticeably, two phenotypes of projection neurons express different dopamine receptors, D 1 receptors in striatonigral neurons and D 2 receptors in striatopallidal neurons (Gerfen et al., 1990; Aubert et al., 2000; Bertran-Gonzalez et al., 2010) . By interacting with D 1 and D 2 receptors, dopamine controls excitability of striatal neurons and outflow of the basal ganglia.
Amphetamine (AMPH) is a psychostimulant which stimulates dopamine release in the striatum (Sharp et al., 1987; Butcher et al., 1988) and causes addiction in experimental animals and humans. In addition to robust behavioral responses to AMPH in animal studies, AMPH induces considerable changes in cell signaling in striatal neurons. For instance, a systemic administration of AMPH elevated phosphorylation of a subfamily of mitogen-activated protein kinases, i.e., extracellular signal-regulated kinases (ERK), in striatal neurons Valjent et al., 2004) . AMPH also increased phosphorylation of striatal Ca 2+ /calmodulin-dependent protein kinase II .
However, to date, the effect of AMPH on SFK phosphorylation was less clear.
In this study, we investigated the impact of AMPH on SFK Y416 phosphorylation in the rat striatum. We first carried out a concentration-response study to examine concentration-dependent effects of AMPH on Y416 phosphorylation. Second, we conducted a time-course study to characterize the temporal property of AMPH action. Third, the role of D 1 receptors in mediating the effect of AMPH was verified by testing the effect of a D 1 antagonist SCH23390. Fourth, the effect of AMPH on ERK phosphorylation and the role of SFKs in linking AMPH to ERK were examined in the striatum. Finally, the effect of AMPH on Fyn kinase activity was examined in the striatum.
Materials and methods

Animals
Charles River Laboratories (New York, NY) provided us with male Wistar rats. We housed animals (240-330 g) at 23°C and humidity of 50 ± 10%. The Guide for the Care and Use of Laboratory Animals of the NIH was followed throughout the experiment. The Institutional Animal Care and Use Committee approved the animal protocol.
Drug administration and protein extraction
We administered drugs to rats via an intraperitoneal (i.p.) injection. Drugs were given at a volume of 1 ml/kg. An injection of saline (1 ml/ kg) was made in age-matched rats and served as controls. The dose of AMPH was calculated as the salt. AMPH was injected at a dose of 5 mg/ kg. This dose was selected because it is an effective dose at which AMPH consistently caused behavioral stimulation, expression of immediate early genes, and phosphorylation of various phosphoproteins in the rat striatum in vivo (Wang and McGinty, 1995; Xue et al., 2014 Xue et al., , 2016 . Rats were anesthetized and killed by decapitation. Brains after quickly removed were cut into coronal slices, from which the entire striatum or different subdivisions of the striatum, including the caudate putamen (CPu), nucleus accumbens (NAc) core and NAc shell, were dissected (Famous et al., 2008) . Brain tissue was homogenized in a radioimmunoprecipitation assay buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na 3 VO 4 , 1 μg/ml leupeptin, and a protease/phosphatase inhibitor cocktail (Thermo Scientific, Rochester, NY). After homogenates were centrifuged at 800g (10 min, 4°C), supernatants were collected. Protein concentrations were determined. Samples were stored at − 80°C until use.
Striatal slice preparation
Striatal slices were prepared according to our previous reports (Liu et al., 2009; Jin et al., 2013) . Briefly, brains were removed after anesthesia and decapitation and were placed in ice-cold artificial cerebrospinal fluid (ACSF) containing (in mM) 10 glucose, 124 NaCl, 3 KCl, 1.25 KH 2 PO 4 , 26 NaHCO 3 , 2 MgSO 4 , and 2 CaCl 2 , bubbled with 95% O 2 -5% CO 2 , pH 7.4. They were cut into coronal slices (400 µm) using a VT1200S vibratome (Leica, Buffalo Grove, IL) . From the slices, the striatum was dissected and preincubated in an incubation tube at 30°C under constant oxygenation with 95% O 2 -5% CO 2 for 60 min. An additional preincubation was performed with fresh ACSF for 10-20 min. After drugs were added and incubated at 30°C, slices were collected for neurochemical assays.
Immunoprecipitation
Immunoprecipitation was performed as described previously . We homogenized striatal tissue in homogenization buffer containing 0.32 M sucrose, 10 mM HEPES, pH 7.4, 2 mM EDTA, 0.5% Triton X-100 (v/v), 1% sodium deoxycholate, and a protease/ phosphatase inhibitor cocktail (Thermo Scientific). Homogenates were centrifuged at 800g (10 min, 4°C). We then collected supernatants for immunoprecipitation. Proteins were incubated with a mouse antibody against Src or Fyn. Protein-antibody complexes were precipitated with 50% protein A and G agarose/sepharose bead slurry (GE Healthcare Life Sciences, Piscataway, NJ), followed by immunoblots with a rabbit antibody against Src, Fyn, or phosphorylated Y416 (pY416).
Western blot
Western blot was performed as described previously (Jin et al., 2013) . Briefly, proteins were separated on SDS NuPAGE Novex 4-12% gels (Invitrogen, Carlsbad, CA) and were then transferred to polyvinylidene fluoride membranes. After membranes were blocked and washed, membranes were incubated with a primary rabbit or mouse antibody (see below) overnight at 4°C. Membranes were then incubated with an anti-rabble or anti-mouse secondary antibody. Proteins were visualized by an enhanced chemiluminescence reagent (GE Healthcare). Optical density of immunoblot bands was measured using NIH ImageJ analysis software. Values of optical density were normalized to a loading control protein (actin).
Tyrosine kinase activity assay
We used the Takara Universal Tyrosine Kinase Assay Kit (Clontech Laboratory, Inc., Mountain View, CA) to assess Fyn and Src kinase activity as described previously (Liu et al., 2014) . The manufacturer's instructions were followed. Briefly, after anesthesia and decapitation, rat brains were removed. The striatum was dissected and homogenized. A mouse antibody against Fyn or Src was used to immunoprecipitate Fyn or Src from homogenates, respectively. Immunopurified Fyn or Src proteins and ATP were added to microplate wells covered with an immobilized tyrosine kinase substrate poly(Glu-Tyr). After incubation at 37°C for 30 min, wells were washed, blocked, and incubated with a horseradish peroxidase-conjugated anti-phosphotyrosine antibody. Phosphorylated substrates in absorbance were measured at 450 nm.
Antibodies and pharmacological agents
Rabbit or mouse primary antibodies were used. These antibodies include rabbit antibodies against Src (Cell Signaling Technology, Danvers, MA), Fyn (Santa Cruz Biotechnology, Santa Cruz, CA), phosphorylated ERK1/2 (pERK1/2) at Thr202/Tyr204 (Cell Signaling), ERK1/2 (Cell Signaling), pY416 (Cell Signaling), or β-actin (SigmaAldrich, St. Louis, MO), or mouse antibodies against Src (Cell Signaling) or Fyn (Santa Cruz). A rabbit antibody against pY416 reacts with the Src family members when phosphorylated at the conserved activation residue: Y416 (chicken Src), Y419 (rat Src), and Y420 (rat Fyn). Pharmacological agents were purchased from Sigma-Aldrich (St. Louis, MO). These agents include D-amphetamine sulfate, R(+)-SCH23390 hydrochloride, SKF81297, and 3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP2). All agents were freshly prepared at the day of experiments.
Statistics
Data (expressed as means ± S.E.M.) were analyzed statistically. The statistical method we used was a one-way analysis of variance followed by a Tukey's multiple comparison post hoc test for comparing multiple groups or a two-tailed unpaired Student's t-test with P < 0.05 as a Rats received a single injection of AMPH at 5 mg/kg (i.p.) and were killed at different time points (15, 60, and 180 min) after AMPH administration. Note that AMPH elevated pY416 levels in a concentration-and time-dependent manner, while AMPH had no effect on total Fyn and Src protein expression. Representative immunoblots are shown at left of quantified data of pY416, Fyn, and Src. Data are presented as means ± S.E.M. (n = 3-7 per group). * P < 0.05 versus saline. statistically significant level.
Results
Effects of AMPH on SFK phosphorylation: a concentration-response study
To determine the effect of AMPH on SFK Y416 phosphorylation, we added AMPH to rat striatal slices at different concentrations. We collected slices 15 min after AMPH incubation for the following Western blot analysis of changes in pY416 levels. We found that AMPH at 0.1 µM induced an insignificant change in pY416 levels (Fig. 1A) . AMPH at 1 µM seemed to increase pY416 levels, although it did not reach a statistically significant level. A marked and consistent increase in pY416 levels was seen in slices treated with 10 µM AMPH as compared to control slices. No significant changes in total amounts of Fyn and Src proteins were found following AMPH incubation at all concentrations surveyed. These results demonstrate that AMPH possesses the ability to concentration-dependently upregulate SFK Y416 phosphorylation in striatal neurons.
Effects of AMPH on SFK phosphorylation: a time-course study
Striatal slices were treated with saline or AMPH (10 μM) for 15 or 60 min. We found that AMPH treatment for 15 min induced a robust increase in pY416 signals, while AMPH treatment for 60 min did not (Fig. 1B) . Thus, the AMPH-induced Y416 phosphorylation in rat striatal slices was transient and reversible. We next wanted to determine whether AMPH alters SFK phosphorylation in the adult rat striatum in vivo and whether the effect of AMPH is time-dependent. To this end, we subjected rats to a single injection of AMPH at 5 mg/kg (i.p.). We then killed rats at different time points (15, 60, and 180 min) after AMPH administration to assess changes in pY416 levels in the striatum. As shown in Fig. 1C , AMPH induced a considerable increase in pY416 levels at 15 min. This increase declined to a level insignificantly different from the normal level at 60 min. No change in pY416 levels was observed at 180 min. Total Fyn and Src proteins remained stable during the entire time course surveyed. These results demonstrate that AMPH stimulates striatal SFK phosphorylation in animals in vivo and AMPH elevates SFK phosphorylation via a time-dependent manner.
Effects of AMPH on SFK phosphorylation in subdivisions of the striatum
To further characterize the effect of AMPH, we explored the impact of AMPH on SFK phosphorylation in striatal subdivisions, including the CPu, NAc core, and NAc shell. In the CPu, an i.p. injection of AMPH (5 mg/kg, 15 min) substantially elevated pY416 levels, while AMPH had no effect on total Fyn and Src protein expression ( Fig. 2A) . Similar results were observed in the NAc core and shell. AMPH increased pY416 levels in these subdivisions, while sparing total Fyn and Src expression (Fig. 2B for the NAc core and Fig. 2C for the NAc shell). These data indicate that AMPH alters SFK Y416 phosphorylation throughout the striatum.
Effects of AMPH on phosphorylation of immunopurified Fyn and Src
Both Fyn and Src contain the conserved autophosphorylation site Y416 subjected to the regulation by changing cellular input (Roskoski, 2005; Okada, 2012) . To determine whether either or both of these two kinases were altered in pY416 phosphorylation in response to AMPH, we immunopurified Fyn and Src proteins from striatal neurons. We then used immunoprecipitated Fyn and Src proteins to probe changes in pY416 phosphorylation in Western blot. In a protein pool immunoprecipitated by a Fyn antibody, strong Fyn immunoreactive signals were detected by the following immunoblot, while no Src signals were seen (Fig. 3A) . Similarly, in Src antibody-precipitated samples, Src but not Fyn signals were observed. These data confirmed the selectivity of the Fyn and Src antibodies in immunopurifying respective proteins. A single injection of AMPH (5 mg/kg, i.p.; 15 min) substantially elevated pY416 levels in immunoprecipitated Fyn (Fig. 3B) . In contrast, pY416 levels in immunoprecipitated Src showed a minimal change in AMPHtreated rats relative to saline-treated rats (Fig. 3C) . These results indicate that AMPH selectively upregulates Y416 phosphorylation in Fyn rather than Src proteins.
Effects of a D 1 antagonist on AMPH-stimulated SFK phosphorylation
To define the role of D 1 receptors in mediating the AMPH-stimulated SFK phosphorylation, we subjected rats to an injection of a D 1 antagonist SCH23390 (0.5 mg/kg, i.p.) 30 min prior to AMPH (5 mg/kg, i.p.). Rats were killed 15 min after AMPH administration. Changes in pY416 levels were investigated in the striatum using Western blots. SCH23390 showed a minimal impact on the basal level of pY416 (Fig. 4A) . However, pretreatment with SCH23390 blocked the Y416 phosphorylation response to AMPH as the pY416 level in rats treated with SCH23390 + AMPH largely returned to the level in rats treated with saline + saline. There were no significant changes in total Fyn and Src expression among all drug treatment groups. These data indicate the role of D 1 receptors in processing the effect of AMPH on striatal SFK Y416 phosphorylation. In support of this, a D 1 agonist SKF81297 mimicked the effect of AMPH. As shown in Fig. 4B , SKF81297 (10 μM, 20 min) increased pY416 levels in striatal slices.
Effects of AMPH on Fyn and Src kinase activity
Upregulation of Fyn Y416 autophosphorylation by AMPH is reasoned to be accompanied by an increase in Fyn kinase activity. To confirm this, effects of AMPH on Fyn kinase activity were assayed. Rats were treated with AMPH (5 mg/kg, i.p.) and were killed at 15 min. The striatum was dissected and Fyn proteins were purified using immunoprecipitation with an anti-Fyn antibody. Kinase activity of purified Fyn was then assessed using a kinase assay kit. A significant increase in Fyn kinase activity in the striatum was seen in AMPH-treated rats as compared to saline-treated rats (Fig. 5A) . In contrast to Fyn, immunopurified Src proteins did not show an increase in kinase activity (Fig. 5B) . These results confirm that AMPH concomitantly increases Fyn kinase activity.
Effects of AMPH on ERK phosphorylation: a role of SFKs
SFKs activated by AMPH may have a functional consequence, i.e., sequentially regulating a signaling molecule downstream to SFKs. ERKs are expressed in postmitotic striatal neurons. Like SFKs, ERKs are sensitive to AMPH. Acute injection of AMPH consistently enhanced phosphorylation of ERKs in striatal neurons Valjent et al., 2004) . To explore whether the ERK is one of downstream targets of SFKs in response to AMPH stimulation, we investigated the effect of SFK inhibition on the AMPH-stimulated ERK phosphorylation. To this end, we first wanted to confirm that AMPH stimulates ERK phosphorylation in our models. As shown in Fig. 6A , AMPH concentration-dependently increased ERK2 phosphorylation in rat striatal slices, while AMPH had no effect on total ERK2 expression. Adding AMPH (0.1 μM) to slices (15 min) did not stimulate ERK2 phosphorylation. AMPH at a high concentration (10 μM), although not a middle concentration (1 μM), significantly increased pERK2 levels. AMPH treatment for 15 min but not 60 min enhanced pERK2 levels in striatal slices (Fig. 6B) . In the animal model, AMPH (5 mg/kg, i.p.; 15 min) also increased pERK2 levels in the striatum (Fig. 6C) . Furthermore, the role of dopamine D 1 receptors in mediating the AMPH effect was validated by the finding that pretreatment with the D 1 antagonist SCH23390 (0.5 mg/kg, i.p.; 30 min prior to AMPH) prevented the AMPH-stimulated increase in striatal ERK2 phosphorylation. SCH23390 alone did not affect the basal level of pERK2. No significant changes in total ERK2 levels were induced by any drug treatments. These results establish a D 1 -mediated effect of AMPH on ERK2 phosphorylation in striatal neurons.
We then tested whether inhibition of SFKs has any impact on the AMPH-stimulated ERK phosphorylation. Adding a widely used SFK inhibitor PP2 (Hanke et al., 1996) to striatal slices (0.1, 1, or 10 μM, 30 min) induced a concentration-dependent reduction of SFK Y416 phosphorylation (Fig. 7A) , while PP2 had no effect on expression of total Fyn proteins. This demonstrates an effective inhibition of SFKs by PP2 in the striatum. Remarkably, using an effective concentration of PP2 (10 μM), we found that the AMPH-stimulated ERK2 phosphorylation was significantly reduced in slices pretreated with PP2 as compared to slices pretreated with vehicle (Fig. 7B) . PP2 alone did not alter basal levels of pERK2. PP2 and AMPH alone or together had no effects on total ERK2 expression. These findings support that activation of SFKs at least in part mediates the effect of AMPH on ERK2 phosphorylation.
Discussion
AMPH may influence SFK activity. This possibility was investigated in this study. In rat striatal slices, application of AMPH elevated SFK Y416 phosphorylation in a concentration-dependent fashion. This effect of AMPH can be replicated in an in vivo model as a single systemic injection of AMPH induced a time-dependent increase in Y416 phosphorylation in the adult rat striatum. The increase in Y416 phosphorylation occurred selectively in immunopurified Fyn but not Src and could be seen in all subdivisions of the striatum (CPu, NAc core, and NAc shell). The upregulated Y416 phosphorylation was accompanied by an increase in Fyn kinase activity and was mediated via D 1 receptors. In addition, AMPH stimulated striatal ERK phosphorylation. This effect was mediated, at least in part, via a signaling mechanism involving activation of SFKs since pharmacological inhibition of SFKs significantly reduced the AMPH-stimulated ERK phosphorylation. Data obtained from this study support the importance of SFK/Fyn in AMPH action. Moreover, since AMPH is a pharmacotherapy for individuals with attention-deficit hyperactivity disorder (Faraone, 2018) , our results pave the way for future studies to elucidate the SFK/Fyn-associated molecular mechanisms underlying the therapeutic effect of AMPH.
Early studies have investigated the effect of cocaine on SFK phosphorylation. A single dose of cocaine (20 mg/kg, i.p.; 10 min) increased pY416 levels in the mouse striatum (Pascoli et al., 2011) . Adding cocaine to rat ventral tegmental area slices (10 μM, 10 min) elevated Y416 phosphorylation in immunopurified Fyn and Src (Schumann et al., 2009) . Similarly, cocaine following an acute injection (15 mg/kg, i.p.; 15 min) enhanced pY416 levels in the ventral tegmental area (Schumann et al., 2009 ). Thus, cocaine possesses the ability to upregulate SFK Y416 phosphorylation. Compared to cocaine, AMPH was less studied for its potential impact on SFK phosphorylation. In this study, we found that SFK Y416 phosphorylation in rat striatal slices or the striatum of adult rats was substantially elevated in response to AMPH. Thus, AMPH like cocaine can stimulate SFK Y416 phosphorylation in striatal neurons. It is known that both cocaine and AMPH enhance synaptic dopamine levels in the striatum, although through different mechanisms (Sharp et al., 1987; Butcher et al., 1988; Boja and Kuhar, 1989) . These stimulants are believed to stimulate SFK Y416 phosphorylation via the similar pathway involving dopamine.
Striatal D 1 and D 2 receptors are expressed in different projection neurons: D 1 receptors in striatonigral neurons and D 2 receptors in striatopallidal neurons (Gerfen et al., 1990; Aubert et al., 2000; BertranGonzalez et al., 2010) . D 1 receptors upon stimulation by selective agonists upregulated Fyn Y416 phosphorylation in mouse cultured striatal neurons (Pascoli et al., 2011) , rat hippocampal slices (Yang et al., 2012) , and the rat striatum (Mao and Wang, 2015) . In contrast, D 2 receptors downregulated Fyn Y416 phosphorylation in the striatum (Hattori et al., 2006; Wang, 2015, 2016) Thus, cAMP and PKA are believed to form an intracellular signaling pathway linking D 1 and D 2 receptors to SFKs. Indeed, PKA has been shown to upregulate phosphorylation of Fyn (serine 21) and Src (serine 17), which further promoted autophosphorylation at Y416 (Schmitt and Stork, 2002; Yeo et al., 2011) . Moreover, a PKA activator upregulated Fyn in spinal neurons (Yang et al., 2011) . Thus, it is possible that AMPH that releases dopamine in the striatum (Sharp et al., 1987; Butcher et al., 1988) upregulated in Y416 phosphorylation in response to AMPH in this study. While the reason for different responses of Fyn and Src to AMPH is unclear, Fyn is certainly a target preferentially regulated by dopamine signaling in striatal neurons in a number of observations. For instance, Fyn was expressed in the striatum at a much higher level than Src (Pascoli et al., 2011) . D 1 agonists increased Fyn but not Src phosphorylation in striatal and hippocampal neurons (Pascoli et al., 2011; Yang et al., 2012; Mao and Wang, 2015) and elevated GluN2B expression in prefrontal cortical neurons through a Fyn-but not Src-sensitive mechanism (Hu et al., 2010) . D 2 antagonists elevated Fyn but not Src phosphorylation in the striatum (Hattori et al., 2006; Wang, 2015, 2016) . In addition, PKA positively regulated Fyn but not Src in spinal neurons (Yang et al., 2011) . Apparently, Fyn represents a preferred SFK member in striatal neurons that is sensitive to dopamine signals and mediates a dynamic D 1 -ERK coupling (see below). Another important finding in this study is that SFKs link AMPH/D 1 to ERKs. To explore the functional consequence of SFKs following activation by AMPH, we investigated whether activated SFKs lead to activation of a signaling effector downstream to SFKs. We found that inhibition of SFKs with an inhibitor PP2 partially reduced a D 1 -dependent phosphorylation response of ERKs to AMPH. Thus, the AMPH-activated SFKs seem to contribute to subsequently stimulating ERKs. Given that the AMPH-stimulated ERK phosphorylation was also D 1 receptor-dependent (this study), AMPH is likely to stimulate D 1 receptors and then SFKs, which contributes to activation of downstream ERKs. 
